Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Literature DB >> 14688144

Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Miroslav S Sarac¹, Juan R Peinado, Stephen H Leppla, Iris Lindberg.

Abstract

The anthrax toxin protective antigen precursor is activated by proteolytic cleavage by furin or a furin-like protease. We present here data demonstrating that the small stable furin inhibitor hexa-D-arginine amide delays anthrax toxin-induced toxemia both in cells and in live animals, suggesting that furin inhibition may represent a reasonable avenue for therapeutic intervention in anthrax.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2004 PMID： 14688144 PMCID： PMC343991 DOI： 10.1128/IAI.72.1.602-605.2004

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

25 in total

1. Designing a polyvalent inhibitor of anthrax toxin.

Authors: M Mourez; R S Kane; J Mogridge; S Metallo; P Deschatelets; B R Sellman; G M Whitesides; R J Collier
Journal: Nat Biotechnol Date: 2001-10 Impact factor: 54.908

2. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough.

Authors: Sandriyana Soelaiman; Binqing Q Wei; Pamela Bergson; Young-Sam Lee; Yuequan Shen; Milan Mrksich; Brian K Shoichet; Wei-Jen Tang
Journal: J Biol Chem Date: 2003-04-03 Impact factor: 5.157

Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

1. Designing a polyvalent inhibitor of anthrax toxin.

2. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough.

Review 3. Development of an improved vaccine for anthrax.

4. A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen.

Review 5. Quickening the pace of anthrax research: three advances point towards possible therapies.

6. Role of furin in delivery of a CTL epitope of an anthrax toxin-fusion protein.

Review 7. Anthrax toxin: a tripartite lethal combination.

8. Role of toxin functional domains in anthrax pathogenesis.

9. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity.

10. The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo.

1. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

2. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.

3. Domain flexibility modulates the heterogeneous assembly mechanism of anthrax toxin protective antigen.

4. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.

5. Time for endothelial cell proprotein convertase PC5/6 in cardiovascular medicine?

6. Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays.

7. Elongated and Shortened Peptidomimetic Inhibitors of the Proprotein Convertase Furin.

Review 8. Obstructing toxin pathways by targeted pore blockage.

Review 9. Designing inhibitors of anthrax toxin.

10. Small molecule inhibitors of anthrax lethal factor toxin.